Glaxo Wellferon Launch For Hepatitis C Awaits Manufacturing Change

The launch of Glaxo Wellcome's hepatitis C treatment Wellferon (interferon alfa-n1, lymphoblastoid) will await the implementation of a manufacturing change, Glaxo said following Wellferon's March 25 approval.